About Pherecydes Pharma
Pherecydes Pharma is a publicly listed company based in Romainville (France) founded in 2006. French, early-stage biotech developing bacteriophage treatments against multi-drug resistant bacterial infections. Pherecydes Pharma has raised $16.4 million across 6 funding rounds from investors including GO CAPITAL, European Union and ACE Management. Pherecydes Pharma offers products and services including Live Draw Sydney, Data Sydney, and Betting Services. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial.
Company details
Pherecydes Pharma is a French, early-stage biotech developing bacteriophage treatments against multi-drug resistant bacterial infections. The main bacteria they are targeting include E.coli and P. aeruginosa which are common, and fatal, infections in burn victims. Their phage therapy clinical trial, phase III for burn victims, called PHAGOBURN was funded by the European Govt. (EUR 3.85 M). in Jun.2015, they launched the project PNEUMOPHAGE, targeted at developing phage therapies for acute respiratory infections ventilator-acquired pneumonia caused by P. aeruginosa. Since Jan.2015, they are part of the PHOSA project aimed at developing phage treatments for Diabetic Foot Ulcers and Bone Joint infections, caused by staphylococci species.
- Headquarters Romainville, France
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website pherecydes-pharma.com
- Social LinkedIn Facebook
- Total Equity Funding$16.4M (USD)
in 6 rounds
- Latest Funding Round$56.62K (USD), Grant
Dec 2021
- InvestorsGO CAPITAL
& 10 more
Products & Services of Pherecydes Pharma
Pherecydes Pharma offers a comprehensive portfolio of products and services, including Live Draw Sydney, Data Sydney, and Betting Services.
Real-time streaming of Sydney lottery results for users.
Platform providing historical and current Sydney lotto results.
Online tools for lottery betting and predictions.
Funding Insights of Pherecydes Pharma
Pherecydes Pharma has successfully raised a total of $16.4M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $56.62 thousand completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $16.4M
- Total Rounds 6
- Last Round Grant — $56,620
- First Round $2.7M
(Jun 2007)
- Investors Count 11
All 6 funding rounds of Pherecydes Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2021 | $56,620 | Grant | – | – | |
| Nov 2018 | $2.79M | Grant | – | – | |
| Jan 2018 | $10.6M | Series B | – | GO CAPITAL | |
| Mar 2015 | $3.1M | Series B | – | ACE Management, Auriga Partners | – |
| Jan 2012 | $1.15M | Grant | – | – | |
| Jun 2007 | $2.7M | Seed | – | – | – |
11 investors in total: 11 institutional.
Investors in Pherecydes Pharma
Pherecydes Pharma has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include GO CAPITAL, European Union and ACE Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Private equity firm focused on energy transition and sustainable investments across Europe. | omnescapital.com | |||
| fadiese.fr | ||||
A co-investment fund is managed for innovative SMEs in Ile-de-France. | prvf.fr | Paris, France | ||
Venture capital investments are managed by Auriga Partners in France. | 1998 | aurigapartners.com | Paris, France | |
Private equity investments are directed toward multiple sectors. | 2003 | gocapital.fr | Rennes, France | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
UAV development, embedded systems, and autonomy software services in the technology sector. | 2013 | acemsolutions.com | Bengaluru, India | |
| participationsbesancon.tcc.mode | ||||
Investment portfolios are managed for clients in Paris, France. | 2000 | acemanagement.fr | Paris, France |
Investor details for Pherecydes Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pherecydes Pharma
3 people are tracked at Pherecydes Pharma (3 in leadership).
| Name | Role | Group |
|---|---|---|
Céline BREDA | Director of Industrial Operations | Leadership |
Pascal Birman | Chief Medical Officer | Leadership |
Frédérique Vieville | Regulatory Affairs and Quality Director | Leadership |
Complete people profiles for Pherecydes Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Pherecydes Pharma
4 dated milestones of Pherecydes Pharma across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Pherecydes Pharma is founded.
- Funding First funding round of $2.7M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $57K.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pherecydes Pharma
Complete news archive for Pherecydes Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pherecydes Pharma
Pherecydes Pharma was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Pherecydes Pharma is headquartered in Romainville, France. It is registered at Romainville, Ile-de-france, France.
Pherecydes Pharma is a funded company, having raised a total of $16.4M across 6 funding rounds to date. The company's 1st funding round was a Seed of $2.7M, raised on Jun 2007.
Pherecydes Pharma is a French, early-stage biotech developing bacteriophage treatments against multi-drug resistant bacterial infections. The main bacteria they are targeting include E.coli and P. aeruginosa which are common, and fatal, infections in burn victims. Their phage therapy clinical trial, phase III for burn victims, called PHAGOBURN was funded by the European Govt. (EUR 3.85 M). in Jun.2015, they launched the project PNEUMOPHAGE, targeted at developing phage therapies for acute respiratory infections ventilator-acquired pneumonia caused by P. aeruginosa. Since Jan.2015, they are part of the PHOSA project aimed at developing phage treatments for Diabetic Foot Ulcers and Bone Joint infections, caused by staphylococci species.
Pherecydes Pharma offers Live Draw Sydney, Data Sydney, and Betting Services.
Pherecydes Pharma has 11 investors. Key investors include GO CAPITAL, European Union, ACE Management, Ace management solutions, and EIC Fund.